Rigel Pharmaceuticals (RIGL) Share-based Compensation (2010 - 2026)

Rigel Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 3.97% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $12.8 million (up 21.36% YoY), while the FY2025 annual figure was $12.7 million, up 2.57% from the prior year.
• Share-based Compensation was $3.5 million for Q1 2026 at Rigel Pharmaceuticals, up from $2.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.1 million in Q1 2024 to a low of $1.9 million in Q4 2023.
• Historically, Share-based Compensation has averaged $2.9 million across 5 years, with a median of $2.7 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation sank 52.62% in 2023, then jumped 86.15% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $4.1 million in 2022, then tumbled by 52.62% to $1.9 million in 2023, then increased by 7.97% to $2.1 million in 2024, then soared by 31.67% to $2.7 million in 2025, then gained by 25.76% to $3.5 million in 2026.
• The last three Share-based Compensation figures came in at $3.5 million (Q1 2026), $2.7 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.